Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$94.23−2.10 (-2.18%)
Close on Nov 16, 2026Market cap $14.81BP/E 72.5Yield –
Kiniksa Pharmaceuticals International gross margin
Gross margin is gross profit as a percentage of revenue.
Kiniksa Pharmaceuticals International's gross margin for the twelve months ending Sep 30, 2026 was 90.2%. For fiscal 2025 it was 88.5%, against 85.6% the year before. The highest annual figure on record is 89.6% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88.5% | +2.9 |
| FY2024 | Dec 31, 2024 | 85.6% | −2.0 |
| FY2023 | Dec 31, 2023 | 87.6% | −2.0 |
| FY2022 | Dec 31, 2022 | 89.6% | +13.2 |
| FY2021 | Dec 31, 2021 | 76.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 90.3% | +1.5 |
| Q2 FY2026 | Jun 30, 2026 | 90.3% | +2.2 |
| Q1 FY2026 | Mar 31, 2026 | 90.3% | +3.3 |
| Q4 FY2025 | Dec 31, 2025 | 89.6% | +4.2 |
| Q3 FY2025 | Sep 30, 2025 | 88.8% | +6.7 |
| Q2 FY2025 | Jun 30, 2025 | 88.1% | −0.5 |
| Q1 FY2025 | Mar 31, 2025 | 87.0% | +0.3 |
| Q4 FY2024 | Dec 31, 2024 | 85.4% | −3.1 |
| Q3 FY2024 | Sep 30, 2024 | 82.1% | −4.4 |
| Q2 FY2024 | Jun 30, 2024 | 88.7% | −0.6 |
| Q1 FY2024 | Mar 31, 2024 | 86.7% | +1.3 |
| Q4 FY2023 | Dec 31, 2023 | 88.5% | −0.6 |
| Q3 FY2023 | Sep 30, 2023 | 86.4% | −6.6 |
| Q2 FY2023 | Jun 30, 2023 | 89.2% | +7.9 |
| Q1 FY2023 | Mar 31, 2023 | 85.4% | +6.1 |
| Q4 FY2022 | Dec 31, 2022 | 89.2% | +12.0 |
| Q3 FY2022 | Sep 30, 2022 | 93.0% | +25.0 |
| Q2 FY2022 | Jun 30, 2022 | 81.4% | – |
| Q4 FY2021 | Dec 31, 2021 | 79.4% | – |
| Q3 FY2021 | Sep 30, 2021 | 77.1% | – |
| Q2 FY2021 | Jun 30, 2021 | 68.0% | – |
See a number that looks wrong?